MedPal Enters At-Home Blood Testing Market
MedPal AI plc is expanding into the at-home blood testing market with the launch of a clinically validated weight loss blood test, initially available to existing app users. This new offering, which uses a virtually painless collection device and analysis by a UKAS-accredited laboratory, delivers results within 48 hours directly to the MedPal app, integrating with data from over 100 wearables. This initiative adds a third revenue stream alongside the company's AI wellness app and automated pharmacy operations, with a broader range of diagnostic tests planned for introduction throughout 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
MedPal Enters At-Home Blood Testing
MedPal AI (AIM: MPAL, FRA: Z1N), the UK digital health and AI company, today announces its entry into the at-home blood testing market with the launch of the MedPal weight loss blood test.
Designed for users of GLP-1 medications such as Mounjaro and Wegovy, who require regular blood tests to monitor their health, the clinically validated kit is the first in a diagnostics range planned for introduction by the Company through the course of 2026. It adds a third revenue stream alongside the Company's AI wellness app and automated pharmacy operations at MedPal.clinic.
Samples are collected at home using the virtually painless Tasso+ device and analysed by a UKAS-accredited laboratory (ISO 15189). The results are delivered directly into the MedPal app within 48 hours, combining with data from over 100 wearables powered by Google's Vertex AI to create comprehensive health profiles and personalised recommendations.
Initially the kits are to be introduced exclusively to existing MedPal app users. A broader range of tests - covering general health, men's health, women's hormonal health and wellness panels - will roll out throughout 2026.
Jason Drummond, CEO & Founder of MedPal AI commented
"Blood testing is the missing layer in consumer health. By combining wearables, blood biomarkers, AI insights and pharmacy fulfilment in one ecosystem, we can now take users seamlessly from insight to diagnosis to treatment.".
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.